Kornimate/medical-research-clean huggingface dataset:
effect of target therapy on patients undergoing synchronic hepatectomy for colorectal liver metastases

Conditions: Colorectal Cancer; Liver Tumor

Summary: the aim of this study is to explore whether target therapy in combination with chemotherapy as treatment could improve survival or tumor response in patients undergoing synchronic hepatectomy for colorectal liver metastases.

in patients with colorectal cancer (crc), the liver is the most common site of hematogenous metastases. approximately half of patients develop hepatic metastases during the course of the disease, and hepatic metastases are responsible for death in at least two thirds of crc patients. over the past decade, due to the introduction of irinotecan-based or oxaliplatin-based combination chemotherapy, the median survival among patients with colorectal liver metastases (clm) has increased from 6 \~8 months to more than 20 months5.in recent years, target therapy has rapidly gained attention for the treatment of clm and is under active investigation. although numerous publications have reported the efficacy of target therapy in combination treatment for clm patients, most of these studies focused solely on those patients without undergoing resection of liver metastases. in contrast, little work has concentrated on exploring the effection of target therapy for clm patients undergoing synchronic hepatectomy.

Eligibility criteria:
inclusion criteria: * age between 18 - 75 years old * performance status (ecog) 0\~1 * colorectal adenocarcinoma pathologically * without any chemotherapy or radiotherapy * liver metastases undergoing radical resection * colorectal cancer undergoing radical resection * no other metastases * suitable for chemotherapy * agreed by patients exclusion criteria: * age below 18 years old or greater than 75 years old * haven't pathological diagnosis of colorectal adenocarcinoma with liver metastase * with any chemotherapy or radiotherapy * with other metastasis * unresectable colorectal cancer or liver metastases * unsuitable for chemotherapy or target therapy * not agreed by patients

Keywords: colorectal liver metastases chemotherapy cetuximab bevacizumab
partner ii trial: placement of aortic transcatheter valves ii - s3 intermediate

Conditions: Symptomatic Severe Aortic Stenosis

Summary: the purpose of this trial is to determine the safety and effectiveness of the edwards sapien 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, and severe aortic stenosis, and those with intermediate risk.

this study design consists of piis3i cohort. the piis3i cohort is a single arm non-randomized, historical-controlled study. patients recruited to the treatment arm will receive an edwards sapien 3 thv with either transfemoral, transapical or transaortic delivery access. to ensure that patients are of "intermediate" risk, an sts score of 4 - 8% has been selected.

Eligibility criteria:
inclusion criteria 1. patient has senile degenerative aortic valve stenosis with echocardiographically derived criteria: mean gradient \>40 mmhg or jet velocity greater than 4.0 m/s and an initial aortic valve area (ava) of \<0.8 cm2 or indexed eoa \< 0.5 cm2/m2 qualifying echo must be within 60 days of the date of the procedure. 2. patient is symptomatic from his/her aortic valve stenosis, as demonstrated by nyha functional class ii or greater. 3. the heart team agrees (and verified in the case review process) that valve implantation will likely benefit the patient. 4. the study patient or the study patient's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the institutional review board (irb) of the respective clinical site. 5. the study patient agrees to comply with all required post-procedure follow-up visits including annual visits through 5 years and analysis close date visits, which will be conducted as a phone follow-up. exclusion criteria: 1. heart team assessment of inoperability (including examining cardiac surgeon). 2. complex coronary artery disease 1. unprotected left main coronary artery 2. syntax score \> 32 (in the absence of prior revascularization) 3. hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation, or mechanical heart assistance within 30 days of screening evaluation. 4. need for emergency surgery for any reason.

Keywords: sapien 3 transfemoral transapical transaortic novaflex tavi aortic stenosis thv aortic valve transcatheter heart valve tavr
quality of life and device acceptance in patients with icd undergoing remote icd fu

Conditions: Anxiety; Depression

Summary: this study investigates whether an additional remote follow-up of patients with implantable cardioverter-defibrillators (icds) has beneficial effects on quality of life (qol), levels of anxiety and depression and device acceptance. patients are randomized to either conventional in-office fu only or additional remote surveillance, follow-up duration is 12 months. the influence of other variables (age, sex,..) is evaluated regarding their influence on study endpoints.

the rising number of implantable cardiac devices leads to an increasing amount of device-related workload, e.g. regular in-office follow-ups (fu). new means of icd fu strategies are necessary to handle the increasing burden. icd remote monitoring promises a time- and cost efficient alternative to conventional in-office fu strategies. many studies have already shown benefits on fu burden reduction, on saving of costs and time, and recently on total mortality. the impact of remote icd fu on quality of life, anxiety and depression levels and device acceptance is still under discussion. the aim of this trial is to investigate the influence of additional remote icd surveillance on the primary endpoint health related quality of life (hrqol), further on levels of anxiety and depression and on device acceptance.

Eligibility criteria:
inclusion criteria: * patients willing to participate * patients with new-implantation of an icd or device replacement due to battery depletion between may 2011 and april 2013 * sufficient knowledge of the german language * expectancy of life \>1 years at good clinical status * written informed consent exclusion criteria: * age \<18 years * subjects not able to give written informed consent * subjects without sufficient german language skills

Keywords: remote icd follow-up hrqol health related quality of life depression anxiety device acceptance telemedicine telemonitoring
evaluation of salivary rnas in the presence of an adnexal mass of ovarian origin

Conditions: Ovarian Cancer; Ovarian Cyst Benign; Borderline Ovarian Cancer

Summary: ovamiarn is a multicentre, prospective, longitudinal, non-interventional, observational study carried out in 8 obstetrics and gynecology departments in france; in order to describe the evolution of salivary mirna expression between the pre-operative and post-therapy visits according to the type of mass. in time, the clinical application will be to significantly reduce the time to diagnosis and improve the care pathway for ovarian adnexal mass. the study population consists of patients with an ovarian adnexal mass diagnosed by clinical examination and imaging (pelvic ultrasound and/or mri) and requiring surgical management in routine care. the patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations (imaging or biology) necessary according to the context, which are carried out according to the recommendations of the has, cngof. in this study, the management and follow-up of patients : * are not imposed by the study: the doctor remains free to make medical prescriptions (treatments and examinations) and to determine the interval between consultation visits, * are not modified in comparison with the usual follow-up, except for the performance of the collection of saliva


Eligibility criteria:
inclusion criteria: * patient over 18 years of age, * a patient with an ovarian adnexal mass diagnosed by clinical examination and imaging and likely to be ovarian cancer, a borderline tumour or a benign cyst, * patient with an indication for surgery * patient has dated and signed the consent form, * patient affiliated to the healthcare system, exclusion criteria: * pregnant patient * patient infected with human immunodeficiency virus (hiv), * patient with significant difficulties in reading or writing the french language. * patient with another diagnosed cancer * patient with a history of cancer less than 5 years old

Keywords: cancer rna machine learning algorithms ovarian
pharmacokinetics, safety and efficacy of pol7080 in patients with ventilator associated pseudomonas aeruginosa pneumonia

Conditions: Ventilator Associated Pneumonia; Lower Respiratory Infection

Summary: to investigate the pharmacokinetic characteristics of pol7080 co-administered with soc during 10 to 14 days of treatment in vap patients due to suspected or documented pseudomonas aeruginosa infection


Eligibility criteria:
inclusion criteria: 1. male and female patients ≥18 years of age diagnosed with vap , i.e., pneumonia that arises more than 96 hours after endotracheal intubation documented or suspected to be due to pseudomonas aeruginosa 2. respiratory specimen suitable for culture and gram stain collected before starting the treatment 3. written informed consent from the patient's legally acceptable representative or a relative exclusion criteria: 1. patients with known hypersensitivity to fluoroquinolones, carbapenems, cephalosporin, penicillin (beta-lactam antibiotics) or aminoglycoside antibiotics (i.e. all available soc antibiotics); patients with a clinically significant history of drug allergies and history of anaphylactic reaction and patients with active allergic conditions at the time of screening 2. known or suspected pulmonary conditions which are likely to interfere with the therapeutic response or might have additional impact on pharmacokinetics 3. patients with acute physiology and chronic health evaluation ii (apache ii) score \>25 4. presence of septic shock at the time of evaluation for study entry 5. history of lung transplant 6. patients with known hiv infection with cd4+ (cluster of differentiation 4) cell count \< 200/mm3 7. concomitant morbidity of such severity that the patient is likely to die or present with serious medical conditions within 7 days of study entry 8. patients with impaired renal function 9. patients who are currently enrolled in, or have not yet completed at least 30 days since ending another investigational device or drug trial or are receiving other investigational agent

Keywords: ventilator associated pneumonia (vap) lower respiratory infection pol7080 pseudomonas aeruginosa nosocomial pneumonia
effects of a 2-week relaxing music intervention on anxiety, stress, and gut symptoms in aerobic exercisers

Conditions: Gastrointestinal System--Abnormalities; Anxiety; Visceral Pain

Summary: the objective of the study is to determine the impacts of a 2-week relaxing music intervention on stress, anxiety, and gut symptoms in individuals who regularly perform structured aerobic exercise. gut symptoms like bloating, reflux, cramping, nausea, etc. are relatively common during prolonged aerobic exercise. in addition, previous research has established that levels of anxiety and stress are associated with a higher occurrence of these gut symptoms. relaxing music has reduced anxiety in certain populations, but currently, no studies are available on its effects on anxiety, stress, and gut symptoms in people who regularly do aerobic exercise.


Eligibility criteria:
inclusion criteria: * be at least 18 years of age * do 120+ minutes per week of planned/structured aerobic exercise of at least moderate intensity * have had at least mild anxiety over the past 2 weeks (gad-7 score of 5 or more) * not currently on a psychotropic medication, or if they are on one, they must have been on a stable dose for the past three months * not currently listening to music for relaxation purposes regularly (\>60 minutes per week) * have at least sometimes experienced gut symptoms (nausea, gas, bloating, cramping, side stitching, urge to defecate, etc.) during aerobic exercise sessions over the last month * have access to the internet exclusion criteria: * not at least 18 years of age * don't do 120+ minutes per week of planned/structured aerobic exercise of at least moderate intensity * haven't had at least mild anxiety over the past 2 weeks (gad-7 score of 5 or more) * have recently started taking a psychotropic medication (within past 3 months) * currently listening to music for relaxation purposes regularly (\>60 minutes per week) * have never or rarely experienced gut symptoms (nausea, gas, bloating, cramping, side stitching, urge to defecate, etc.) during aerobic exercise sessions over the last month * don't have internet access
concomitant use of gardasil (v501, human papillomavirus [types 6, 11, 16, 18] recombinant vaccine) with combined diptheria, tetanus, pertussis and poliomyelitis vaccine in adolescents (v501-024)(completed)

Conditions: Neoplasms, Glandular and Epithelial; Diphtheria; Tetanus; Whooping Cough; Poliomyelitis

Summary: data from this study are expected to demonstrate that gardasil (v501, human papillomavirus \[types 6, 11, 16, 18\] recombinant vaccine), when administered concomitantly with a combined diphtheria, tetanus, pertussis, and poliomyelitis vaccine in adolescents remains immunogenic and well-tolerated and it does not impair the immunogenicity of the concomitant vaccines.


Eligibility criteria:
inclusion criteria: * must be healthy boys or girls, 11-17 years of age * must be a virgin with no intention of becoming sexually active during the study period * must have been properly vaccinated against diphtheria, tetanus, pertussis and polio exclusion criteria: * must not have received a vaccine against diphtheria, tetanus, pertussis and polio in the past 5 years * must not have received any prior human papillomavirus (hpv) vaccine
screening for early gastric cancer in shaanxi province

Conditions: Early Gastric Cancer

Summary: this study collect the relevant data of local residents over 20 years old in 11 regions of shaanxi province, the basic information of the subjects was collected by filling in the questionnaire, and serum helicobacter pylori antibody detection was completed at the same time. the expert group determined the high-risk population of gastric cancer after comprehensive evaluation. all the high-risk population of gastric cancer without contraindications underwent electronic gastroscopy in the designated hospital after signing the informed consent. by collecting and analyzing data, early gastric cancer screening was completed and a new gastric cancer risk assessment model was established to evaluate the prevalence of dyspepsia, gastroesophageal reflux disease and precancerous lesions in the natural population of shaanxi province, as well as helicobacter pylori infection, radical treatment and recurrence rate.

from october 2020 to october 2026, after obtaining the informed consent of local residents over 20 years old in 11 regions of shaanxi province, the subjects' social demographic characteristics, living and eating habits, and previous diseases were collected by filling in questionnaires, and serum helicobacter pylori antibody was detected at the same time. after comprehensive assessment by the expert group, the high-risk population of gastric cancer was determined. all high-risk population of gastric cancer without contraindications underwent electronic gastroscopy in designated hospitals after signing informed consent. by collecting and analyzing data, early gastric cancer screening was completed and a new gastric cancer risk assessment model was established to evaluate the prevalence of dyspepsia, gastroesophageal reflux disease and precancerous lesions in the natural population of shaanxi province, as well as helicobacter pylori infection, radical treatment and recurrence rate. in this project, the research group was responsible for formulating the plan, designing the questionnaire, and conducting quality control and grass-roots guidance tour. guanghua science and technology foundation provided public welfare assistance, and distributed and collected questionnaires with the assistance of grass-roots clinics. finally, the research group sorted out and analyzed the data.

Eligibility criteria:
inclusion criteria: * local resident over 20 years old. * obtain verbal informed consent of the subject. exclusion criteria: * refused to participate in this research project. * questionnaires or serological tests for helicobacter pylori antibodies were not completed. * this study was not completed due to other reasons.

Keywords: early gc,hp infection,fd, gerd , precancerous lesions
the comparison between computed tomography and colonoscope in detecting colorectal tumors in patients with fit+

Conditions: Patients at Risk of Colorectal Cancer

Summary: colonoscopy is the mainstay modality of choice in colorectal cancer screening worldwide. however, the rate of colonoscopy for colorectal cancer screening is very low (approximately 5-10%) because of the limited local medical resources (such as endoscopists and regional endoscope). this observational diagnostic test study aims to compare the diagnostic yield of routine computed tomography and colonoscopy in detecting colorectal tumors in patients at risk of colorectal cancer (aged more than 50 years and fit+). the main question\[s\] it aims to answer are: 1. to compare the diagnostic yield between the routine computed tomography and colonoscopy. 2. to compare the procedure-related adverse events between the routine computed tomography and colonoscopy.

all enrolled patients underwent routine ct scans of whole abdomen, then subsequently under went a colonoscopy on the next day

Eligibility criteria:
inclusion criteria: 1. fit test + 2. normal platelet count and normal result of pt, ptt exclusion criteria: 1. pregnancy or lactation 2. uncontrolled diabetes mellitus, hypertension, asthma, congestive heart failure 3. recent coronary artery disease within 3 months 4. egfr lesser than 30 ml/min/1.73m2 5. hemophilia or uncontrolled or uncorrected coagulopathy

Keywords: colorectal tumor colorectal cancer ct scan colonoscopy
a bilateral dispensing comparison of comfilcon a over senofilcon c contact lenses

Conditions: Astigmatism Bilateral

Summary: the aim of this study is to evaluate the subjective acceptance of comfilcon a contact lenses when worn on a daily wear modality over one month.

this study is a 30-subjects prospective, double-masked (investigator and participant), bilateral, randomized, one month cross-over dispensing study comparing subject acceptance of comfilcon a against senofilcon a contact lenses.

Eligibility criteria:
inclusion criteria: a person is eligible for inclusion in the study if he/she: 1. is at least 17 years of age and has full legal capacity to volunteer; 2. has had a self-reported oculo-visual examination in the last two years. 3. has read and signed an information consent letter; 4. is willing and able to follow instructions and maintain the appointment schedule; 5. is an adapted soft contact lens wearer, who currently wears contact lenses for a minimum 3 days/week and 8 hours/day and who anticipates no difficulty wearing cls for 6 days/week, 10 hours /day. 6. is willing to wear contact lens in both eyes for the duration of the study; 7. has a minimum astigmatism of - 0.75, determined by refraction; 8. can be fit with the two study contact lens types in the powers available; 9. has a distance visual acuity of 0.20 logmar (approx 20/30) or better, determined by refraction; 10. can achieve a distance visual acuity of 0.20 logmar (approx 20/30) or better in each eye with the study contact lenses. 11. has clear corneas and no active\* ocular disease; exclusion criteria: a person will be excluded from the study if he/she: 1. is participating in any concurrent clinical trial; 2. has any known active\* ocular disease and/or infection; 3. has a systemic condition that in the opinion of the investigator may affect a study measure; 4. is using any systemic or topical medications that in the opinion of the investigator may affect a study measure; 5. has known sensitivity to fluorescein dye or products to be used in the study; 6. appears to have any active\* ocular pathology, ocular anomaly or severe insufficiency of lacrimal secretion (severe dry eye) that would affect the wearing of contact lenses; 7. is pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit); 8. is aphakic; 9. has undergone refractive error surgery; 10. has participated in the previous quena study.
irrigated ablation system evaluation for atrial fibrillation (af)

Conditions: Paroxysmal Atrial Fibrillation

Summary: the purpose of this study is to test the safety and effectiveness of an irrigated ablation system for the treatment of symptomatic paroxysmal atrial fibrillation.


Eligibility criteria:
inclusion criteria: * age 18 years or older * signed patient informed consent form * able and willing to comply with all pre-, post-, and follow-up testing and requirements * failure of at least one anti-arrhythmic medication (aad) for paroxysmal atrial fibrillation\* \[class i or iii, or av nodal blocking agents such as beta blockers (bb) and calcium channel blockers (ccb)\] as evidenced by recurrent symptomatic paroxysmal atrial fibrillation\*, or intolerable side effects due to aad * subjects with symptomatic paroxysmal atrial fibrillation (paf)\* * paf is defined as recurrent atrial fibrillation (af) that terminates spontaneously within seven days. exclusion criteria: * atrial fibrillation (af) secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause * previous ablation for af * history of any valvular cardiac surgical procedure * coronary artery bypass grafting (cabg) procedure within the last six months * awaiting cardiac transplantation or other cardiac surgery within the next 12 months * left atrial thrombus * history of a documented thromboembolic event within the past one (1) year * diagnosed atrial myxoma * an implanted implantable cardioverter defibrillator (icd) * significant pulmonary disease, (e.g. restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms * significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study * women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable) * acute illness or active systemic infection or sepsis * unstable angina * myocardial infarction within the previous two months * left ventricular ejection fraction (lvef) \<40% as determined by pre-procedure transthoracic echocardiogram (tte) * history of blood clotting or bleeding abnormalities * contraindication to anticoagulation (i.e. heparin or warfarin) * contraindication to computed tomography/magnetic resonance angiography (ct/mra) procedure * life expectancy less than 12 months * enrollment in an investigational study evaluating another device or drug * uncontrolled heart failure or new york heart association (nyha) class iii or iv heart failure * an intramural thrombus tumor, or other abnormality that precludes catheter introduction or manipulation * presence of a condition that precludes vascular access * left atrial size ≥ 50 mm as determined by pre-procedure tte